Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 14;1(21):1796–1806. doi: 10.1182/bloodadvances.2017006981

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by The American Society of Hematology

PMC Copyright notice

Figure 5. — Flagellin treatment preferentially induces hematopoietic progenitor cell proliferation in bone marrow. Bone marrow cells from WT B6 mice treated with flagellin for 15 hours were analyzed by flow cytometry using antibodies including SLAM-code CD48 and CD150 to determine hematopoietic stem cell and hematopoietic progenitor cell proliferation. The following markers were used: LT-HSCs, CD34⁻Flt3⁻CD150⁺CD48⁻; ST-HSCs, CD34⁺Flt3⁻CD150⁻CD48⁻; MPP1, CD34⁺Flt3^-CD150⁺CD48⁻; MPP2, CD34⁺Flt3⁻CD150⁺CD48⁺; MPP3, CD34⁺Flt3⁻CD150⁻CD48⁺; and MPP4, CD34⁺Flt3⁺CD150⁻CD48⁺. Shown are BrdU incorporation of MPP1, MPP2, MPP3, ST-HSCs (A), and MPP4 (B) in PBS- vs flagellin-treated mice, statistics of total LSK cell number (C); LT-HSC, ST-HSC, MPP1, MPP2, MPP3, and MPP4 cell numbers (D); and BrdU incorporation (E) in PBS- vs flagellin-treated mice. Statistics were analyzed by unpaired Student t test (**P < .01; ***P ≤ .001). Error bars represent SEM. BM, bone marrow.